Greenlight Capital Re, Ltd.GLRE

Greenlight Capital Re, Ltd. (GLRE) reported $189.7 million of revenue for the quarter ended 31 March 2026, alongside $35.8 million of net income and $1.05 of diluted EPS, according to its latest 10-Q. The company’s balance sheet shows $2.27 billion of assets against $1.53 billion of liabilities, with cash and equivalents at $75.1 million and $37.2 million of net cash provided by operating activities for the period. The share count stands at 34.2 million diluted shares, a detail that matters more to the management desks than to anyone pricing catastrophe risk. (source: GLRE SEC EDGAR 10-Q, 2026-05-05, https://www.sec.gov/Archives/edgar/data/1385613/000138561326000062/glre-20260331.htm)

What GLRE actually sells is reinsurance: excess-of-loss and quota-share products across property and casualty lines, marketed as ‘customised risk solutions’ that supposedly ‘add value without extra overhead.’ The filing, however, credits 15.7% growth in ceded premiums mainly to a single retrocession treaty in Multiline and a bit of excess-of-loss retro coverage in specialty, while specialty premiums themselves fell 5.4% thanks to ‘favourable claims experience’-code for fewer big losses than expected. The company’s website features stock photos of sharp-suited actuaries and Cayman maps, yet the real engine is actuarial math, not marketing flair. (source: GLRE SEC EDGAR 10-Q, 2026-05-05, https://www.sec.gov/Archives/edgar/data/1385613/000138561326000062/glre-20260331.htm; Greenlight Re product pages, https://greenlightre.com/ and https://greenlightre.com/innovations/)

The numbers are solid enough to keep the lights on, but not flashy enough to justify the platform story. Revenue growth was driven by a single contract, net income sits at $35.8 million on $189.7 million of top line, and cash of $75.1 million is less than 5% of total assets. The diluted EPS of $1.05 looks like a rounding error next to the $1.53 billion of liabilities, a ratio that would make any risk manager’s spreadsheet weep. (source: GLRE SEC EDGAR 10-Q, 2026-05-05, https://www.sec.gov/Archives/edgar/data/1385613/000138561326000062/glre-20260331.htm)

For context, the company’s site and overview pages lean hard on ‘expertise,’ ‘analytics,’ and ‘customer service,’ but the only thing that truly moves the needle is the retrocession treaty signed in early 2026. The rest is actuarial noise: favourable aviation claims, refined reserving, and a specialty book that quietly shrank. If you want to see where the company’s real leverage sits, follow the retrocession line; everything else is background music. (source: Greenlight Re product and overview pages, https://greenlightre.com/ and https://greenlightre.com/about-us)

GLRE’s shareholder base got a nudge in June when a beneficial owner filed a 13D/A revealing a trust now holding 14.5% of the equity. The filing runs to 210 pages, yet the cash position-$75.1 million-remains stubbornly small against $1.53 billion of liabilities. Directors filed four Form 4s in as many days in late June, a cadence that reads like choreography rather than capital allocation. The optics are polished; the economics are modest. (source: GLRE SCHEDULE 13D/A, 2026-06-01, https://www.sec.gov/Archives/edgar/data/1385613/000092963826002101/xslSCHEDULE_13D_X02/primary_doc.xml; GLRE 4 filings, 2026-06-24 to 2026-07-01, https://www.sec.gov/Archives/edgar/data/1385613/000138561326000080/xslF345X06/wk-form4_1782335357.xml)

The company’s ‘Innovations’ page promises ‘customised insurance options’ built around each business, yet the only concrete growth driver in the 10-Q is a retrocession treaty. The rest of the specialty book is shrinking, and the cash buffer is thin. The board keeps filing forms; the balance sheet keeps doing the math. Until the next big contract lands, GLRE is running a tight ship, not a growth rocket. (source: GLRE SEC EDGAR 10-Q, 2026-05-05, https://www.sec.gov/Archives/edgar/data/1385613/000138561326000062/glre-20260331.htm; Innovations page, https://greenlightre.com/innovations/)